New drug may keep rare lymphoma at bay after first treatment

NCT ID NCT07293403

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This phase II trial is testing whether the drug duvelisib can help prevent peripheral T-cell lymphoma from coming back after initial therapy. About 25 adults with certain types of T-cell lymphoma will take duvelisib as maintenance treatment. The study will track how long patients stay cancer-free and how well they tolerate the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: duvelisib (a kinase inhibitor)
What this could lead to: If successful, this could provide a way to keep peripheral T-cell lymphoma from coming back after initial treatment, potentially extending remission.
What could go wrong: This is a small, early-phase (phase II) trial with only 25 participants, so results may not apply broadly. Duvelisib can cause side effects like infections or liver issues, and some patients may need to stop treatment due to toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR HELPER T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR HELPER T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.